Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allarity Therapeutics, Inc. (NASDAQ: ALLR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Phase 2 clinical-stage biopharmaceutical company focused on stenoparib and its DRP® companion diagnostic platform, Allarity uses SEC reports to communicate material events, financing transactions, and periodic financial information to investors.
Among the key documents available are Form 8-K current reports, where Allarity has disclosed events such as FDA Fast Track designation for stenoparib in advanced ovarian cancer, new clinical data presentations from its Phase 2 ovarian cancer trial, conference participation on biomarkers and precision medicine, licensing and laboratory services agreements for DRP® algorithms, and private placement securities purchase agreements. Filings like NT 10-Q (Form 12b-25) explain timing of quarterly reports and provide context on the status of financial statement reviews.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping users quickly understand disclosures related to clinical development, capital structure, registration rights, and governance changes. Real-time updates from EDGAR ensure that new Allarity filings are added as they become available, including quarterly and annual reports when filed, as well as any future Forms 10-K, 10-Q, or additional 8-Ks.
Investors researching ALLR can use this page to review how Allarity describes its business focus on stenoparib and DRP®, track unregistered equity offerings and registration rights agreements, and monitor other material events reported under SEC rules. The combination of original documents and AI-generated overviews is intended to make complex regulatory language more accessible while preserving the underlying source information.
Allarity Therapeutics, Inc. announced that the first patients have been dosed with stenoparib in combination with temozolomide in a U.S. Department of Veterans Affairs–funded investigator-initiated Phase 2 trial for relapsed small cell lung cancer, an area described as having high unmet medical need.
The trial is fully funded through the VA’s Special Emphasis Panel on Precision Oncology and is open for enrollment across 11 VA medical centers in the United States. Allarity highlights stenoparib’s dual PARP and WNT pathway inhibition, its favorable safety profile compared with earlier PARP inhibitors, and its ability to cross the blood-brain barrier as potential advantages in this setting.
Allarity Therapeutics is registering 255,103 shares of common stock for resale by a single selling stockholder. These shares were issued on December 23, 2025 as “Additional Shares” in a private placement at $0.98 per share, which previously generated approximately $250,000 in gross proceeds for the company.
The resale registration is purely for the stockholder’s benefit; Allarity will not receive any proceeds when these shares are sold. As context, 16,080,980 shares of common stock were outstanding as of February 11, 2026, and the Nasdaq closing price that day was $0.90 per share.
In earlier tranches of the private placement, Allarity sold 760,916 shares and 801,584 pre-funded warrants for roughly $2.5 million in gross proceeds and may sell up to $6.0 million of additional stock over time under a separate equity line agreement. The company remains a clinical-stage oncology business focused on stenoparib and operates as an emerging growth and smaller reporting company, highlighting ongoing capital needs and potential future dilution.
Allarity Therapeutics, Inc. reported that enrollment has opened for a new Phase 2 clinical trial. The study evaluates a combination of stenoparib and temozolomide to treat patients with recurrent small cell lung cancer.
The company released a press statement about this development, which is included as an exhibit to the report and incorporated by reference.
Allarity Therapeutics, Inc. has entered a common stock purchase agreement with Tumim Stone Capital that allows the company, at its discretion, to sell up to $6.0 million of common stock over 24 months. Under Nasdaq’s 19.99% exchange cap, this prospectus supplement registers 3,214,588 shares for resale by Tumim.
Sales prices will be based on a discount to volume-weighted average trading prices, so the actual number of shares issued will vary with the stock price. As of January 27, 2026, Allarity had 16,080,980 shares outstanding and a public float of approximately $20.1 million.
The company warns that issuing shares to Tumim and Tumim’s subsequent resales could significantly dilute existing stockholders and pressure the share price. Any proceeds Allarity receives from selling shares to Tumim are expected to be used for working capital and general corporate purposes, including potential debt repayment and operating expenses.
Allarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital, creating an equity line of credit that allows the company, at its sole discretion, to sell up to $6,000,000 of newly issued common shares over time.
Shares sold under the agreement will be priced at a discount to market, equal to either 95% of the lowest one-day volume‑weighted average price or 97% of the lowest three‑day volume‑weighted average price, subject to volume and dollar limits per draw of up to $1,000,000 or $2,000,000.
The investor cannot exceed 4.99% ownership of outstanding common stock, or 9.99% if it elects that higher cap. Issuances are also limited by an Exchange Cap tied to 19.99% of pre‑agreement shares outstanding, unless stockholders later approve a waiver and, if needed, an increase in authorized shares. Allarity paid a $45,000 commitment fee for this financing flexibility.
Allarity Therapeutics, Inc. reported an equity award to senior executive Jeremy R. Graff, its President and Chief Development Officer. On January 7, 2026, Graff received 133,333 shares of common stock in the form of restricted stock units at a price of $0 per share under the company’s Amended and Restated 2021 Equity Incentive Plan. These RSUs will vest in three equal one-third installments on the first, second, and third anniversaries of the grant date, conditioned on his continued relationship with the company. Following this award, Graff beneficially owns 381,644 shares of Allarity Therapeutics common stock, held directly.
Allarity Therapeutics (ALLR) filed its Q3 2025 report, highlighting a smaller quarterly net loss and stable liquidity. Net loss was $2.8 million for the quarter and $7.9 million year-to-date. Cash and cash equivalents were $16.9 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months.
Operating cash outflow was $11.6 million for the nine months. The company raised capital via an ATM program with $9.7 million net proceeds year-to-date and completed a private placement of 1,562,500 shares at $1.60 per share for roughly $2.5 million gross. Allarity also executed a share repurchase program, buying 2,600,763 shares for $2.706 million, with $2.294 million remaining authorized.
The FDA granted Fast Track designation to stenoparib for advanced ovarian cancer, supporting development interactions. The company reported a material weakness in internal controls related to accounting for the repurchase program and is implementing remediation. Shares outstanding were 16,111,461 as of September 30, 2025; 15,811,886 were reported outstanding as of November 13, 2025.
Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc. (ALLR), reported transactions dated 09/30/2025. 39,494 restricted stock units vested and were reported as acquired, and 14,613 shares were disposed of at $1.58 per share, leaving 24,881 shares owned directly after the transactions. The filing also shows 223,430 restricted stock units/derivative securities beneficially owned following the reported transactions. The RSUs convert one-for-one to common stock and stem from grants of 118,483 RSUs on 09/30/2024 and 144,441 RSUs on 01/22/2025, each vesting in three equal annual installments beginning on the first anniversary of the respective grant dates.
Allarity Therapeutics, Inc. filed an S-3 shelf registration describing an offering that includes 760,916 shares of Common Stock and 801,584 Pre-Funded Warrants exercisable for Common Stock at an exercise price of $0.0001 per share. The company’s authorized capital structure includes 250,000,000 shares of Common Stock and 500,000 shares of undesignated preferred stock. The prospectus enumerates the distribution methods permitted under the plan, including ordinary brokerage transactions, block trades, principal purchases and exchange distributions. The document lists estimated offering expenses including $20,000 for accounting fees and $50,000 for legal fees. A table of exhibits identifies corporate charter amendments, bylaws, a specimen stock certificate, forms of pre-funded warrant, a securities purchase agreement and a registration rights agreement dated September 22, 2025. The filing is signed by the CEO, CFO and multiple directors with signatures dated September 25, 2025.
Allarity Therapeutics, Inc. reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from the company’s ongoing Phase 2 trial in advanced ovarian cancer. The presentation took place at the American Association for Cancer Research 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.
The company also noted that a press release dated September 22, 2025, containing further details on the Phase 2 trial update has been issued and is included as an exhibit.
Allarity Therapeutics, Inc. reported that Dr. Jeremy Graff, its President and Chief Development Officer, presented new and updated clinical data from the company’s ongoing Phase 2 trial in advanced ovarian cancer. The presentation took place at the American Association for Cancer Research 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado.
The company also noted that a press release dated September 22, 2025, containing further details on the Phase 2 trial update has been issued and is included as an exhibit.